Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer

Area of Science:

• Oncology
• Metabolic pathways
• Cancer genetics

Background:

• KRAS mutations are implicated in ovarian cancer progression.
• These mutations can drive metabolic reprogramming, enhancing metastatic potential.
• Understanding these metabolic alterations is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate metabolic reprogramming in KRAS-mutant ovarian cancer.
• To explore the combined mechanism of action of metformin and a glutaminase 1 inhibitor (CB-839).
• To evaluate the therapeutic efficacy of this combination in preclinical models.

Main Methods:

• Comparative analysis of glucose and glutamine metabolism-related enzyme expression in KRAS-mutant versus wild-type ovarian cancer cells.
• Assessment of aerobic oxidative capacity.
• In vitro and in vivo studies evaluating the effects of metformin and CB-839, alone and in combination.

Main Results:

• KRAS-mutant ovarian cancer cells exhibit elevated expression of key glucose and glutamine metabolism enzymes.
• These cells show increased aerobic oxidative capacity.
• Metformin and CB-839 combination therapy significantly inhibited proliferation and aerobic oxidation in KRAS-mutant cells, with superior efficacy in a mouse model compared to single agents.

Conclusions:

• KRAS mutations induce significant metabolic reprogramming in ovarian cancer, characterized by enhanced glucose and glutamine metabolism.
• The combination of metformin and CB-839 effectively targets these metabolic vulnerabilities.
• This combination therapy demonstrates promising preclinical efficacy against KRAS-mutant ovarian cancer.